Keytruda has been Merck’s defining growth engine, but it also concentrates risk. The article argues that with the drug’s patent cliff approaching in 2028, Merck needs a platform that can support revenue beyond the PD-1 era. Its $6.7 billion cash acquisition of Terns Pharmaceuticals is framed not as a routine bolt-on deal, but as a strategic move to secure a foothold in the next cycle of hematologic precision therapy.
The centerpiece is TERN-701, an oral STAMP inhibitor for chronic myeloid leukemia, or CML. Although still in early clinical development, the asset fits a market where long treatment duration, adherence, and line expansion can create lasting value. Merck is therefore buying more than a Phase I/II program. It is buying a chance to shape a treatment class before the competitive structure fully hardens.
A Second Wave for STAMP
CML is one of the clearest examples of what targeted therapy can accomplish. Since imatinib, tyrosine kinase inhibitors have turned a once highly fatal disease into a chronic condition for many patients. Yet standard TKIs still leave unresolved issues, especially around depth of response, resistant disease, and the burden of long-term treatment.
STAMP changed that conversation by targeting the myristoyl pocket of BCR-ABL1 rather than the ATP-binding site. Novartis validated the approach with asciminib, marketed as Scemblix, showing that the mechanism could reduce off-target toxicity and retain activity against certain resistant mutations. The article notes that Scemblix reached $1.285 billion in 2025 sales and that Novartis lifted its peak-sales forecast to $4 billion, evidence that the class already has meaningful commercial credibility.
TERN-701 matters because it may improve on that first proof of concept. According to the article, the CARDINAL Phase I/II program showed a 64% major molecular response rate in evaluable patients, with 24-week MMR reaching 75% at a specific dose level. The data are especially notable because the study included heavily pretreated and resistant patients. The reported 60% cumulative MMR in evaluable patients previously treated with asciminib is presented as the clearest sign that TERN-701 may be differentiated rather than merely follow-on.
Safety and convenience strengthen the case. Terns reported mostly low-grade adverse events, little signal in blood pressure or lipase, and a very low discontinuation rate. The article also emphasizes that TERN-701 is not affected by food intake, giving it a practical adherence advantage over fasting-dependent dosing with Scemblix. In a disease managed over years, that kind of usability can carry real commercial weight.
Why CML Can Support a Premium Franchise
The commercial logic of CML is different from that of many solid tumors. Growth is driven not only by new diagnoses, but by the accumulation of patients who remain on therapy for long periods. In effect, it is a chronic treatment pool. Once patients begin treatment, many stay on drug for years, sometimes for more than a decade, which steadily expands the treated population.
That helps explain why the article cites multiple forecasts projecting sustained market growth through the next decade. Generic TKIs may widen access at the lower end, while newer mechanisms such as STAMP defend the premium segment. The more these agents move into earlier treatment lines, the larger the addressable market becomes.
This is why first-line positioning is so important. The article cites analysis suggesting first-line treatment already represents more than 60% of total CML market value. If TERN-701 eventually reaches earlier-line use, its commercial ceiling could expand sharply. The acquisition is therefore a bet on both mechanism and sequencing.
Merck Versus Novartis
Novartis has the first-mover advantage with asciminib and already sits at the center of the current STAMP narrative. Merck is entering later, but possibly at a moment when the treatment pathway is still being written. Physician education is incomplete, real-world evidence is still accumulating, and the balance between later-line rescue use and earlier-line adoption has not been fully settled.
That means the real contest is not just who has the better dataset today. It is who can build the stronger global evidence base, move the class forward into earlier lines, and use commercial scale to define the next standard of care. Novartis has lead time and brand familiarity. Merck brings a global oncology network, commercialization depth, and a pressing need to build beyond Keytruda.
Why Analysts Call the Deal Attractive
The article notes that some Wall Street analysts view the acquisition price as relatively favorable given the asset’s upside. BMO reportedly suggested unadjusted peak sales for TERN-701 could exceed $4 billion. On that logic, Merck may have bought a potentially high-value franchise at a price below what later-stage validation might have demanded.
The risks are obvious: TERN-701 remains an early program, and early oncology data do not always hold up. Even so, the strategic rationale is clear. Merck is not simply replacing one product with another. It is buying a position in a market where durability, tolerability, and earlier-line expansion could shape the next decade of precision hematology. If Keytruda defined the company’s last era, TERN-701 may be its bid to enter the next one.